Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL27734165 | 0.89 | TYR (0.42) | TYRALDH1A1LMNAMAPTGAA | |
| SCHEMBL14204959 | 0.83 | ALDH1A1 (0.46) | TYRALDH1A1LMNAKDM4EKIF11 | |
| SCHEMBL12392170 | 0.83 | ALDH1A1 (0.46) | TYRALDH1A1LMNAMAPTGAA | |
| SCHEMBL6290471 | 0.81 | ALDH1A1 (0.54) | TYRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL469386 | 0.80 | ALDH1A1 (0.72) | ALDH1A1LMNAMAPTGAAKDM4E | |
| SCHEMBL2090911 | 0.79 | TSHR (0.51) | ALDH1A1LMNAMAPTGAAHPGD | |
| SCHEMBL10856575 | 0.78 | ALDH1A1 (0.42) | TYRALDH1A1LMNAMAPTGAA | |
| SCHEMBL694956 | 0.78 | PTGS2 (0.52) | ALDH1A1LMNAKDM4EHPGDNFKB1 | |
| SCHEMBL4739960 | 0.77 | TYR (0.41) | TYRALDH1A1LMNAMAPTGAA | |
| SCHEMBL2095219 | 0.75 | FADS1 (0.49) | TYRALDH1A1MAPTKDM4EKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513054-B1 | BICYCLIC DERIVATIVES USEFUL AS INHIBITORS OF DPP-1 | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| EP-0204571-B1 | SELECTED DIFLUORO DERIVATIVES | ICI AMERICAS INC. (US) | 1992-01-22 | — | — | EP | claimed |
| WO-2022133285-A1 | MOLECULES AND METHODS RELATED TO TREATMNET OF DISORDERS ASSOCIATED WITH JAK-2 SIGNALING DYSFUNCTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20210380588-A1 | Novel Compounds and Uses Thereof | OXFORD FINANCE LLC | 2021-12-09 | — | — | US | disclosed |
| US-10954244-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-2478981-B1 | SILVER-(CONJUGATED COMPOUND) COMPLEX | SUMITOMO CHEMICAL CO (JP) | 2020-12-23 | — | — | EP | disclosed |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | KALA BIO, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10544151-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-10351570-B2 | Compounds and uses thereof | KALA PHARMACEUTICALS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| EP-0147379-A1 | Making nitrodiarylamines | MONSANTO COMPANY (US) | 1985-07-03 | — | — | EP | disclosed |
| US-4248621-A | HERBICIDES | SANDOZ LTD. (CH) | 1981-02-03 | — | — | US | disclosed |
| US-4228103-A | Effecting condensation of nitrohaloarene and formyl derivative of a primary aromatic amine with alkali metal hydroxide | MONSANTO COMPANY (US) | 1980-10-14 | — | — | US | disclosed |
| US-4209463-A | Promoting the formation of nitrodiarylamines from nitrohaloarenes, activated aryl amines and sodium carbonates | MONSANTO COMPANY (US) | 1980-06-24 | — | — | US | disclosed |
| US-4196146-A | Making nitrodiarylamines from formyl derivatives of aromatic amines and nitrohaloarenes by admixing with certain aqueous salt solutions | MONSANTO COMPANY (US) | 1980-04-01 | — | — | US | disclosed |
| US-4187248-A | FORMANILIDE | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4187249-A | COMPOUNDS OF POTASSIUM, CESIUM, OR RUBIDIUM | MONSANTO COMPANY (US) | 1980-02-05 | — | — | US | disclosed |
| US-4140716-A | Process for making an amide of formic acid and forming nitrodiarylamine therefrom | MONSANTO COMPANY (US) | 1979-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380588-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | TYR 146/4885ALDH1A1 1517/4885LMNA 2524/4885 |
| US-20200157106-A1 | Novel Compounds and Uses Thereof | RB1, VEGFA, UACA | TYR 146/4885ALDH1A1 1517/4885LMNA 2524/4885 |
| US-10544151-B2 | Compounds and uses thereof | RB1, VEGFA, KDR | TYR 106/4885ALDH1A1 1409/4885LMNA 2637/4885 |
| US-10954244-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | TYR 72/4885ALDH1A1 1477/4885LMNA 2569/4885 |
| US-10351570-B2 | Compounds and uses thereof | RB1, VEGFA, FLT4 | TYR 72/4885ALDH1A1 1477/4885LMNA 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.